Evidence map›Paper›PMID 35012557›Full record

ArticleHarm reduction journal2022

Diverse psychotropic substances detected in drug and drug administration equipment samples submitted to drug checking services in Toronto, Ontario, Canada, October 2019-April 2020.

Kristy M Scarfone, Nazlee Maghsoudi, Karen McDonald, Cristiana Stefan, Daniel R Beriault, Ernest Wong, Mark Evert, Shaun Hopkins, Peter Leslie, Tara Marie Watson and 2 more

Abstract read
In one paragraph

Article in Harm reduction journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kristy M ScarfoneCentre On Drug Policy Evaluation, c/o Li Ka Shing Knowledge Institute of St. Michael's Hospital, 30 Bond Street, Toronto, ON, M5B1W8, Canada.
Nazlee MaghsoudiCentre On Drug Policy Evaluation, c/o Li Ka Shing Knowledge Institute of St. Michael's Hospital, 30 Bond Street, Toronto, ON, M5B1W8, Canada.
Karen McDonaldCentre On Drug Policy Evaluation, c/o Li Ka Shing Knowledge Institute of St. Michael's Hospital, 30 Bond Street, Toronto, ON, M5B1W8, Canada.
Cristiana StefanClinical Laboratory and Diagnostic Services, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Daniel R BeriaultDepartment of Laboratory Medicine, St. Michael's Hospital, Toronto, ON, Canada.
Ernest WongClinical Laboratory and Diagnostic Services, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Mark EvertDepartment of Laboratory Medicine, St. Michael's Hospital, Toronto, ON, Canada.
Shaun HopkinsToronto Public Health, Toronto, ON, Canada.
Peter LeslieToronto Harm Reduction Alliance, Toronto, ON, Canada.
Tara Marie WatsonProvincial System Support Program, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Dan WerbCentre On Drug Policy Evaluation, c/o Li Ka Shing Knowledge Institute of St. Michael's Hospital, 30 Bond Street, Toronto, ON, M5B1W8, Canada. Daniel.werb@unityhealth.to.ORCID 0000-0003-0614-9386
Toronto’s Drug Checking Service Working Group

Funding

CIHR
6 · The paper itself

Abstract

backgroundThe overdose crisis has generated innovative harm reduction and drug market monitoring strategies. In Toronto, Ontario, Canada, a multi-site drug checking service (DCS) pilot project was launched in October 2019. The project provides people who use drugs with information on the chemical composition of their substances, thereby increasing their capacity to make more informed decisions about their drug use and avoid overdose. DCS also provides real-time market monitoring to identify trends in the unregulated drug supply.

methodsSample data were obtained through analyses of drug and used drug administration equipment samples submitted anonymously and free of charge to DCS in downtown Toronto from October 10, 2019, to April 9, 2020, representing the first six months of DCS implementation. Analyses were conducted in clinical laboratories using liquid chromatography- and/or gas chromatography-mass spectrometry (LC-MS, GC-MS) techniques.

resultsOverall, 555 samples were submitted, with 49% (271) of samples that were found to contain high-potency opioids, of which 87% (235) also contained stimulants. Benzodiazepine-type drugs were found in 21% (116) of all samples, and synthetic cannabinoids in 1% (7) of all samples. Negative effects (including overdose, adverse health events, and extreme sedation) were reported for 11% (59) of samples submitted for analysis.

conclusionsToronto's DCS identified a range of high-potency opioids with stimulants, benzodiazepine-type drugs, and a synthetic cannabinoid, AMB-FUBINACA. This information can inform a range of evidence-informed overdose prevention efforts.

Indexed as

Drug OverdoseIllicit DrugsPharmaceutical PreparationsAnalgesics, OpioidFentanylHumansLaboratories, ClinicalOntarioPilot ProjectsAnalgesics, OpioidFentanylIllicit DrugsPharmaceutical PreparationsDrug overdoseEtizolamFentanylFlualprazolamSynthetic cannabinoid

Identifiers

PMID35012557
PMCPMC8748183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.